Press release
Geron to Announce Fourth Quarter and Full Year 2021 Financial Results on March 10, 2022
FOSTER CITY, Calif.--(BUSINESS WIRE)-- Geron Corporation (Nasdaq: GERN) today announced that it will release its fourth quarter and full year 2021 financial
About this update from Geron Corporation
[{"type":"text","content":" FOSTER CITY, Calif.--(BUSINESS WIRE)--\nGeron Corporation (Nasdaq: GERN) today announced that it will release its fourth quarter and full year 2021 financial results after the market closes on Thursday, March 10, 2022 via press release, which will be available on the Company’s website at www.geron.com/investors. Geron will host a conference call to discuss the financial results as well as upcoming milestones at 4:30 p.m. ET the same day.\n\nA live webcast of the conference call and related presentation will be available on the Company’s website at www.geron.com/investors/events. An archive of the webcast will be available on the Company’s website for 30 days.\n\nParticipants may access the webcast by registering online using the following link, https://conferencingportals.com/event/SmvlMvWL. Participants that are unable to register online can access the conference call via telephone by dialing domestically +1 (888) 330-2434 or internationally +1 (240) 789-2725. The conference ID is 67335.\n\nAbout Geron\n\nGeron is a late-stage clinical biopharmaceutical company focused on the development and potential commercialization of a first-in-class telomerase inhibitor, imetelstat, in hematologic malignancies. The Company currently is conducting two Phase 3 clinical trials: IMerge in lower risk myelodysplastic syndromes and IMpactMF in refractory myelofibrosis. For more information about Geron, visit www.geron.com.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20220303005990/en/\n\nOlivia Bloom\nChief Financial Officer\[email protected]\[email protected]\n\nSource: Geron Corporation","length":3663,"tagName":"div"}]